EyeGate Pharmaceuticals

Originally incorporated as Optis France S.A. in 1998, the company became EyeGate Pharmaceuticals, Inc. in 2004. In a strategic move in November 2021, EyeGate Pharmaceuticals rebranded to Kiora Pharmaceuticals, Inc., now trading under the NASDAQ ticker KPRX. This name change signaled a sharpened focus on developing novel treatments for ophthalmic diseases, particularly for rare conditions like Retinitis Pigmentosa, alongside more common eye ailments. The company operates as a clinical-stage specialty pharmaceutical firm, concentrating on the development and commercialization of therapies for eye-related disorders. Kiora's business model is centered on advancing its product pipeline through clinical trials to gain regulatory approval and then commercializing these therapies. A key part of its strategy has included strategic acquisitions, such as Jade Therapeutics in 2016 and Panoptes Pharma in 2020, to enhance its development pipeline and technology platforms.

Stephen From, who has a background as an investment banker in biotechnology and CFO at Centelion SAS (a subsidiary of Sanofi-Aventis), led EyeGate as President, CEO, and Chairman for over a decade, taking the company public and overseeing multiple acquisitions. Paul Chaney, with over 30 years of experience in the biopharmaceutical industry, including senior roles at Pharmacia Corporation and as COO of Eyetech Pharmaceuticals, served as Chairman of the Board for EyeGate. The company's leadership team was further strengthened by the founders of its acquired companies, including Dr. Barbara Wirostko, co-founder of Jade Therapeutics, who brought extensive clinical and regulatory experience from her time at Pfizer.

Kiora's product pipeline includes several candidates at various stages of clinical development. KIO-301 is a small molecule photoswitch designed to restore light perception in patients with degenerative retinal diseases. KIO-101 is a non-steroidal, small-molecule inhibitor being developed as an eye drop for ocular surface inflammation, such as dry eye disease. Another product, KIO-201, is a hydrogel eye drop intended to accelerate corneal wound repair after surgeries like PRK. The company's approach often involves leveraging unique delivery systems, such as a cross-linked hyaluronic acid (CMHA-S) platform acquired from Jade Therapeutics, which is designed for sustained release and to protect the ocular surface.

Keywords: Kiora Pharmaceuticals, EyeGate Pharmaceuticals, ophthalmic therapeutics, clinical-stage pharmaceutical, eye disease treatment, Retinitis Pigmentosa, retinal degeneration, dry eye disease, corneal wound repair, small molecule therapy, drug delivery systems, photoswitch technology, KIO-301, KIO-101, KIO-201, non-steroidal eye drops, Stephen From, Paul Chaney, specialty pharma, ocular inflammation, hyaluronic acid hydrogel, pharmaceutical acquisitions, biotechnology